Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

Published:2019-05-20 Issue:1 Volume:10 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Qi Xinyue,Li Fanlin,Wu Yi,Cheng Chen,Han Ping,Wang Jieyi,Yang Xuanming

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-019-10088-1.pdf

Reference38 articles.

1. Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242 (2013).

2. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).

3. Watts, T. H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23–68 (2005).

4. Vinay, D. S. & Kwon, B. S. 4-1BB signaling beyond T cells. Cell. Mol. Immunol. 8, 281–284 (2011).

5. KwonB. S. & WeissmanS. M. cDNA sequences of two inducible T-cell genesProc. Natl Acad. Sci. USA 86, 1963–1967 (1989).

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity;Nanomedicine;2024-09-03

2. Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8⁺T cells and inhibited tumor growth;Journal for ImmunoTherapy of Cancer;2024-08

3. Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity;Nature Communications;2024-07-23

4. Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates;Toxicology and Applied Pharmacology;2024-06

5. Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis;JACC: Basic to Translational Science;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3